Silence Therapeutics to buyback siRNA complement assets

Silence Therapeutics (SLN) announced it will be acquiring back exclusive worldwide rights to two siRNA drug targets under the collaboration agreement with Mallinckrodt Pharmaceuticals (MNK) for complement-mediated diseases. Under the terms of the agreement, Silence will not make any upfront payment to get the two assets back and Mallinckrodt is eligible to receive future success-based milestones and low single digit royalties on net sales if the projects advance. "We want to thank Mallinckrodt for their excellent partnership over the last 3 and a half years," said Craig Tooman, President and CEO of Silence. "We are very excited for the opportunity to now have two wholly owned complement assets to add to our portfolio. We continue to see substantial potential for our mRNAi GOLD(TM) platform across multiple therapeutic areas and look forward to generating more clinical data this year in cardiovascular and hematological diseases."